SNYR (Synergy CHC Corp) Company Projected Revenue

Brandmark of Synergy CHC (SNYR)

Synergy CHC Corp (SNYR) planned sales levels demonstrate a scaling vector for its wellness portfolio via digital marketing, where the 0.03 level serves as a critical benchmark. The company relies on its health brand ecosystem to strengthen its retail position. The development of direct-to-consumer (DTC) sales acts as an additional factor, while the debt load is already priced into the market value of SNYR assets.

synergychc.com - SNYR Company Expected Sales Volume (period 10/24/2024 - 10/03/2026)

Summary analytical data breakdowns for synergychc.com (SNYR)

- stock value and consensus price forecast:
- business market valuation indicators:
Fundamental valuation:Synergy CHC Corporation
Brand item of Synergy CHC Corp

This indicator measures expected revenue, reflecting the intrinsic value of the business through the lens of future cash flows. Comparing this metric with market capitalization allows for the identification of undervalued assets. By analyzing the company's planned sales volume, an investor determines the stability of the operating model or the risk of capital stagnation. For Synergy CHC Corp (SNYR), this confirms the resilience of baseline demand for wellness products. The holding's moderate cyclicality makes this forecast a key filter when assessing the impact of consumer budgets on growth.

Competitor analysis

Projected Sales Volume HLN|KVUE (Kenvue Inc) - Company Future Revenue|Verona Pharma Corp - Company Future Sales Volume|Company Projected Revenue Volume MENS (Jyong Biotech Ltd)|ligand.com - Projected Sales Volume|amneal.com (AMRX) - Company Future Sales Volume|Perrigo (PRGO) - Company Projected Revenue|ALVO (Alvotech S.A.) - Company Projected Revenue|Company Future Sales Volume LQDA|Projected Sales Volume Galapagos Corp|Company Projected Revenue ANI Pharma (ANIP)|Projected Sales Volume MannKind Corporation (MNKD)|Company Projected Revenue Amphastar Pharmaceuticals Inc AMPH|Projected Sales Volume Pacira PCRX|ARS Pharmaceuticals Inc - Projected Sales Volume|TBPH - Projected Sales Volume|AQST (Aquestive Therapeutics) - Company Future Sales Volume|scPharmaceuticals, Inc. (SCPH) - Projected Sales Volume|Company Future Sales Volume TECX|Projected Sales Volume Tonix Pharma|Company Future Sales Volume SXTC (SXT Pharmaceuticals)|EPRX: Company Expected Revenue|BioHarvest Sciences - Company Future Sales Volume|EXOZ: Company Revenue Forecast|ORMP - Company Projected Revenue|ENTX: Company Projected Revenue|HYFT: Projected Sales Volume|Company Future Sales Volume ABVC BioPharma Inc|CPIX (Cumberland Corp) - Projected Sales Volume|Projected Sales Volume quantumbiopharma.com|Projected Sales Volume FGEN|Company Future Sales Volume Telomir Pharmaceuticals, Inc. TELO|Projected Sales Volume RANI (Rani Therapeutics)|Projected Sales Volume rallybio.com RLYB|Lexaria Bioscience Corp. - Projected Sales Volume|PULM: Company Projected Revenue|PTHL (ftzy.com.cn) - Company Future Sales Volume|APM: Company Projected Revenue Volume|LYRA (Lyra Therapeutics Inc) - Projected Sales Volume|Company Revenue Forecast IBO (Impact BioMedical)|Company Future Sales Volume TNFA (TNF Pharmaceuticals)|Projected Sales Volume cbdMD Corp (YCBD)|Projected Sales Volume PRFX (PainReform)|Company Future Sales Auris Medical (CYTO)|LIPO - Company Projected Revenue|Optinose (OPTN) - Company Future Sales Volume|Pieris (PIRS) - Company Projected Revenue|Company Expected Revenue PROC (Procaps Group S.A.)|Company Future Sales Volume PTPI|QLI: Company Future Revenue|Company Projected Revenue acelyrin.com (SLRN)|TFFP (TFF Pharma) - Company Future Revenue